Structural, Stability, Dynamic and Binding Properties of the ALS-Causing T46I Mutant of the hVAPB MSP Domain as Revealed by NMR and MD Simulations

Shixiong Lua1, Haina Qin1, Liangzhong Lim1, Jiahai Shi1, Garvita Gupta1, Jianxing Song1,2*

1 Department of Biological Sciences, Faculty of Science, National University of Singapore, Singapore, Singapore, 2 Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore

Abstract

T46I is the second mutation on the hVAPB MSP domain which was recently identified from non-Brazilian kindred to cause a familial amyotrophic lateral sclerosis (ALS). Here using CD, NMR and molecular dynamics (MD) simulations, we characterized the structure, stability, dynamics and binding capacity of the T46I-MSP domain. The results reveal: 1) unlike P56S which we previously showed to completely eliminate the native MSP structure, T46I leads to no significant disruption of the native secondary and tertiary structures, as evidenced from its far-UV CD spectrum, as well as Cα and Cβ NMR chemical shifts. 2) Nevertheless, T46I does result in a reduced thermodynamic stability and loss of the cooperative urea-unfolding transition. As such, the T46I-MSP domain is more prone to aggregation than WT at high protein concentrations and temperatures in vitro, which may become more severe in the crowded cellular environments. 3) T46I only causes a 3-fold affinity reduction to the Nir2 peptide, but a significant elimination of its binding to EphA4. 4) EphA4 and Nir2 peptide appear to have overlapped binding interfaces on the MSP domain, which strongly implies that two signaling networks may have a functional interplay in vivo. 5) As explored by both H/D exchange and MD simulations, the MSP domain is very dynamic, with most loop residues and many residues on secondary structures highly fluctuated or/and exposed to bulk solvent. Although T46I does not alter overall dynamics, it does trigger increased dynamics of several local regions of the MSP domain which are implicated in binding to EphA4 and Nir2 peptide. Our study provides the structural and dynamic understanding of the T46I-causing ALS; and strongly highlights the possibility that the interplay of two signaling networks mediated by the FFAT-containing proteins and Eph receptors may play a key role in ALS pathogenesis.

Introduction

Amyotrophic lateral sclerosis (ALS) is the most prevalent fatal motor neuron disease, which affects people of all race and ethnic background. Approximately 10% of the cases have hereditary background while the rest are sporadic. Seven ALS-causative genes have been identified to date but the most characterized is ALS1 encoding mutants of Cu/Zn-superoxide dismutase (SOD1). So far, despite intense studies, the exact mechanism underlying ALS pathogenesis remains poorly understood and there is no efficient therapy for ALS. As sporadic and familial ALS affects the same neurons with similar pathology, it is believed that knowledge and therapeutic approaches/agents developed on mutant models can be translated to sporadic ALS [1,2].

Recently, ALS8 was identified from a large Brazilian family with dominant motor neuron diseases, which encodes a mutated VAPB (vesicle-associated membrane protein-associated protein B). The missense P56S point mutation results in a typical ALS phenotype with rapid progression or late onset spinal muscular atrophy [2–5]. Very recently, another mutation T46I on VAPB has been unraveled to also cause ALS in non-Brazilian kindred [6]. The human VAP family proteins were originally identified as homologues of vesicle-associated membrane protein (VAMP)–associated protein (VAP) in Aplysia californica (aVAP33) [7,8], which include VAPA, VAPB, and VAPC. VAPA and VAPB share ~60% sequence identity while VAPB and VAPC are alternatively spliced variants. VAP proteins are ubiquitously expressed, type II integral membrane proteins that localize to the endoplasmic reticulum (ER) and pre-Golgi intermediates [9], which have been implicated in the regulation of neurotransmitter release, ER-Golgi and intra-Golgi transport [10,11]. Moreover, VAP proteins have been shown to target lipid-binding proteins carrying a short motif with two phenylalanines in an acidic tract (FFAT motif) to the ER [12,13]. The FFAT motif with the consensus amino acid sequence EFFDAxE was conserved in several lipid-binding protein families involved in the transfer of lipids between the ER and other organelles [14–18]. The VAP proteins also interact with intracellular proteins [19,20] including Nir1, Nir2, and Nir3 via the FFAT motif which differentially affects the organization of the ER [11].
Despite owning very diverse functions, VAPA and VAPB proteins are composed of three conserved domains, namely an N-terminal immunoglobulin-like β sheet domain with 22% sequence identity to the major sperm protein (MSP), a central coiled-coil domain, and a C-terminal transmembrane domain. After the P56S mutation was identified to be associated with ALS, the VAPB-MSP domain received intensive studies regarding its functions and the biological consequence of the mutation [21–28]. The P56S mutation results in severe aggregation and alteration of unfolded protein response (UPR) in ER [6,21–28]. Strikingly, the cleaved VAPB MSP domain was recently found to act as a novel ligand class for Eph receptors [29]. The connection of VAPB to Eph receptors may shed critical light on the core signaling networks involved in ALS pathogenesis and also represent a promising target for therapeutic interventions [30]. Indeed, Eph receptors constitute the largest family of tyrosine kinases, with 16 members in mammals and chick divided into two classes, EphA and EphB, which are respectively activated by six glycosylphosphatidylinositol-anchored ephrin-A ligands or three transmembrane ephrin-B ligands to mediate an extremely wide spectrum of biological functions through signals that are generated by both receptor and ligand activation [31].

Previously, we have determined the crystal structure of the hVAPB MSP domain, which adopts a well-defined MSP fold with a cooperative urea-unfolding transition [32]. Moreover, with our discovery that insoluble proteins could in fact be solubilized in salt-free water [33–35], we have succeeded in characterizing the P56S mutant by NMR spectroscopy and demonstrated that the P56S mutation completely eliminates the native MSP structure and binding capacity. In particular, the unstructured P56S mutant becomes severely aggregated in buffers mimicking the physiological conditions [32].

In the present study, we aimed to characterize the newly-identified T46I mutant. By extensive CD, NMR characterization and molecular dynamics (MD) simulations, we found that the T46I-MSP domain still retains the native MSP structure with overall dynamics largely unaltered. Nevertheless the T46I mutation on the MSP domain does lead to a reduction of its thermodynamic stability and loss of the cooperative urea-unfolding transition. As such, the T46I-MSP domain is much more prone to aggregation at high protein concentrations and temperatures. Noticeably, the T46I mutation results in only a 3-fold reduction of its binding affinity to the Nir2 peptide, but a significant abolishment of the binding ability to EphA4.

Methods
Cloning, expression, and purification of the WT and T46I MSP domains
The DNA fragment encoding the wild-type (WT) hVAPB MSP domain (residues 1–125) was cloned into a modified pET32a vector (Novagen) as previously described [32]. The T46I mutation on the MSP domain was generated by use of site-directed mutagenesis [36]. The vectors were transformed into E. coli BL21 (DE3) cells (Novagen) for protein expression. Most WT and a mutant vector (Novagen) as previously described [32–35]. The protein concentration is 20 μM for all far-UV CD experiments. To measure the thermodynamic stability of the T46I-MSP domain, a series of far-UV CD spectra were collected by varying the urea concentrations from 0 to 8 M and subsequently the unfolding curve was constructed by plotting the ellipticity values at 222 nm versus the molar concentration of urea [32].

ITC characterization of binding activity
Isothermal titration calorimetry (ITC) experiments were performed using a Microcal VP machine as previously described [35]. The Nir2 peptide (EEEFDFAHE) was purchased from Genesis Biotech Inc. and further purified by HPLC on a reverse-phase C18 column. Titrations were conducted in the buffer (50 mM Tris-HCl, 150 mM NaCl, 2 mM DTT, pH 7.5) at 25°C. The peptide or EphA4 (300 μM) was loaded into the syringe while the wild-type hVAPB MSP peptide (10 μM) was placed in the sample cell. To obtain thermodynamic binding parameters, the titration data after subtracting the blank values were fitted to a single binding site model using the built-in software ORIGIN version 5.0 (Microcal Software Inc.).

NMR experiments
The T46I-MSP sample was prepared in 10 mM phosphate buffer, pH 6.8. All NMR data were collected at 25°C on an 800-MHz Bruker Avance spectrometer equipped with a shielded cryoprobe as described before [32,35]. For HSQC characterization, samples were prepared at a protein concentration of 100 μM while for achieving sequential assignments, triple-resonance experiments including HNCACB and CBCA(CO)NH were acquired on a double-labeled sample at a protein concentration of ~200 μM. The spectral processing and analysis was performed by using the program DANGLE in CCPNMR [39].

To conduct hydrogen-deuterium (H/D) exchange experiments, the 15N-labeled WT- or T46I-MSP domains in the 10 mM (pH 6.8) phosphate buffer was lyophilized and then re-dissolved in D2O. Progress of the exchange process between amide protons and deuterium was followed by collecting a series of successive HSQC spectra starting immediately after the sample re-solubilization in D2O. All exchange experiments were conducted on an 800 MHz Bruker Avance spectrometer at 25°C. The first HSQC spectrum was collected after 15 min, and the last spectra were acquired after 2.5 h.

For NMR HSQC characterization of the binding interactions of WT-/T46I-MSP to the Nir2 peptide; as well as to the EphA4 ligand-binding domain, two-dimensional 1H-15N HSQC spectra of the 15N-labeled WT-/T46I-MSP domains were acquired at a protein concentration of 100 μM in the absence or presence of the
Nir2 peptide, or EphA4 at different molar ratios, including 1:0.5; 1:1; 1:2; 1:4; 1:6; and 1:8. Similarly, the binding interactions were also visualized by collecting HSQC spectra of the 15N-labeled EphA4 ligand-binding domain at a protein concentration of 100 μM in the absence or presence of WT- or T46I-MSP domain at the same molar ratios. By superimposing the HSQC spectra, the shifted or disappeared HSQC peaks could be identified and further assigned to the corresponding residues of the WT-/T46I-MSP domains or EphA4 ligand-binding domain whose assignment was previously achieved [37,40,41].

Results

Structure and thermodynamic stability of the T46I-MSP domain

In the present study, by using site-directed mutagenesis we constructed the T46I-MSP domain by replacing Thr46 with Ile on the WT-MSP domain we previously generated [32]. Subsequently the T46I-MSP domain was expressed in E. coli BL21 cells. Although a large portion of the T46I protein existed in inclusion body, there was a small portion of the soluble T46I form in supernatant. Consequently we purified the soluble T46I protein by Ni2+-affinity column under native condition, followed by FPLC ion-exchange chromatography. The purified T46I domain with His-tag removed has a far-UV CD spectrum highly similar to that of WT (Figure 1a). This strongly indicates that T46I has a native-like secondary structure. Furthermore, the T46I-MSP domain also has a well-dispersed HSQC spectrum (Figure 1b) in which many peaks are even superimposable to those of WT, suggesting that T46I is also well-folded. Despite the aggregation of T46I at protein concentrations higher >300 μM, we managed to collect a pair of triple-resonance NMR spectra, namely HNCACB and CBCA(CO)NH, on a double-labeled sample at a protein concentration of ~200 μM, which thus allowed our successful sequential assignment. Although HSQC peaks of three regions were not detectable for T46I, including residues Ile46-Tyr52, Glu82-Ser84 and C-terminal Ph123-Leu125, Cz and Cβ chemical shifts of the remaining T46I residues are almost identical to those of WT (Figures 1c, 1d and 1e). These results provide the strongest evidence that the T46I-MSP domain assumes a three-dimensional structure highly similar to that of WT.

Thermodynamic stability is an important factor mediating protein aggregation particularly in the crowding cellular environments [48]. Here we assessed the thermodynamic stability of T46I by use of the urea-unfolding method previously for WT [32]. Markedly, unlike WT with a cooperative unfolding transition, T46I shows a non-cooperative transition as well as reduced stability (Figure 2a). T46I starts unfolding at a urea concentration of ~1.6 M and shows no ending even at 8 M, while WT starts at ~3.5 M and ends at ~5.1 M. As a result of losing the cooperative unfolding transition, the precise energy of thermodynamic stability could not be fitted out from the T46I unfolding curve.

The loss of a cooperative unfolding transition of T46I implies that its tight tertiary packing is disrupted to some degree [49,50] and consequently the T46I molecule may be more accessible to partially- or highly unfolded states prone to aggregation. Indeed, we observed that aggregation occurred for T46I at high protein concentrations and temperatures. For example, while at 45°C the WT sample showed no precipitation and has almost no change of the upfield peaks in the one-dimensional NMR proton spectra (Figure 2b), a large portion of the T46I protein precipitated at ~42°C and the remaining protein has a dramatic structural alteration as evidenced from the changes of the upfield peaks (Figure 2c).

The high tendency of T46I to aggregate prevented from further investigations on its dynamics on ps-ns and μs-ms time scales by NMR relaxation measurements which require a sample with a much higher concentration for collecting high-quality data. Therefore, here we utilized NMR hydrogen/deuterium (H/D) exchange and to assess the backbone dynamics for both WT and T46I on minute-hour time scale. As well-established, in solution labile hydrogens such as amide protons on proteins are continually exchanging with the solvent at different rates, depending on a variety of factors associated with their environment including their exposure to the solvent or their involvement in H-bonds.
Consequently, amide H/D exchange experiments offer a sensitive reflection of the exposure degree of amide protons to the solvent [51]. Surprisingly, as seen in Figure 2d, even for WT in the buffer, there are ∼12% of 116 non-proline residues whose HSQC peaks were not detectable. Upon subjecting to H/D exchange, ∼66% of the total residues have completely exchanged with deuterium within the experimental dead time (15 min). These fast-exchange rate residues cover not only most residues on the non-secondary structure regions, but also on the β-strands and helical fragment (Figure 2e). After 2.5 h, amide protons of more residues exchanged and consequently only ∼22% of the total residues have persisted HSQC peaks, which were characterized as slow-exchange-rate residues (Figures 2d and 2e). These results reveal that the hVAPB MSP domain is very dynamic on the min-hr time scale, similar to what we observed on the human ephrin-B2 [52]. Moreover, we have also characterized the amide H/D exchanges for T46I and no significant difference was found (data not shown), suggesting that T46I has a largely unchanged dynamics on the min-hr time scale.

Interactions of WT-/T46I-MSP domains to Nir2 peptide

The VAPB MSP domain was demonstrated to functionally interact with the FFAT-motif containing Nir2 protein [11] and previously we measured the dissociation constant (Kd) between the WT-MSP domain and a Nir2 peptide to be 0.65 μM by ITC [32]. Here we assessed the binding of T46I to the same peptide under the same conditions. The ITC result shows that T46I is still able to bind the peptide but the affinity has a 3-fold reduction, with a Kd of 2.2 μM (Figure 3a).

On the other hand, we also used HSQC titrations to visualize the binding of the WT- and T46I-MSP domains to the Nir2 peptide. As shown in Figures 3b and 3c, in WT, for the residues directly contacting the peptide [12,32], their HSQC peaks mostly disappeared at a molar ratio of 1:2 (WT-MSP/Nir2), while for the residues not directly contacting but close to the binding interface, their HSQC peaks shifted (Figure 3c). Intriguingly, due to the reduced affinity, the addition of the Nir2 peptide only induced the shift, but not disappearance of the T46I HSQC peaks (Figure 3d).

Binding interactions of WT-/T46I-MSP domains to EphA4

Recently, the cleaved MSP domain was identified to serve as a novel ligand for the EphA4 ligand binding domain [29] but the underlying structural basis remains undefined. In the current study, we attempted to gain thermodynamic parameters for the EphA4-WT-MSP binding by ITC but unfortunately a complex ITC profile was obtain (Figure 4a), which implies that the binding may be involved in multi-sites or/and multi-steps. On the other hand, this profile was no longer observed for the T46I-EphA4 interaction [data not shown], implying that the T46I mutation significantly abolishes the binding.

Although previously we have successfully crystallized and determined the crystal structures of the WT-MSP domain [32] as well as EphA4 ligand binding domain in both free state [37] and in complex with ephrin-B2 [40], we failed to crystallize the
EphA4-MSP complex after extensively screened a variety of buffer conditions. As such, here we further gained the molecular details for the binding interaction between EphA4 and MSP by NMR HSQC titrations. First, we monitored the change of the HSQC spectra of the 15N-labeled WT- and T46-MSP domains upon gradually adding the unlabeled EphA4 ligand-binding domain. As shown in Figure 4b, introduction of EphA4 induced shifts of few peaks, but more dramatically disappearance of a set of peaks. If the residues with shifted and disappeared HSQC peaks were mapped back to the MSP structure, it appears that the significantly perturbed residues are located on E-F loop and several β-strands: C-strand carrying Thr46, F- and G-strands (Figure 4c). By contrast, addition of EphA4 to T46I resulted in almost no disappearance the HSQC peaks, only caused slight peak shifts for some residues (Figures 4d and 4e). These results indicate that the T46I mutation dramatically disrupts the binding ability of the MSP domain to EphA4, nicely in agreement with the above ITC result.

We further addressed the binding by monitoring the HSQC spectra of the EphA4 ligand-binding domain. As shown in Figure 5a, addition of the WT-MSP protein even at a ratio of 1:2 (EphA4/WT-MSP) triggered extensive disappearance or intensity-reduction of many EphA4 peaks, together with shifts of few peaks. If the ratio was increased up to 1:8, most EphA4 peaks disappeared. By mapping the residues with shifted or disappeared peaks back to the EphA4 structure, it appears that the significantly affected residues are located over D-E, G-H and J-K loops, which have been previously established to directly contact its ligand ephrins [40]. By a sharp contrast, addition of the T46I-MSP domain caused almost no peak disappearance, but only shifts of few peaks (Figures 5c and 5d), again indicating that the T46I mutation dramatically eliminates the binding capability to EphA4.

To understand the underlying mechanism for the significant disappearance of both MSP and EphA4 HSQC peaks, we measured the radius of the EphA4 ligand-binding domain by dynamic light scattering (DLS) in the presence of both WT- and T46I-MSP domains at different molar ratios but no significant changes were observed (data not shown). This implies that the binding triggers no formation of the tight EphA4-MSP complex and no significant oligomerization. As such, the disappearance of the MSP and EphA4 HSQC peaks is mostly resulting from the increase of conformational exchanges on the μ-ms time scale upon binding.

We also titrated the 15N-labeled EphA4 with the Nir2 peptide but no change was detected for the EphA4 HSQC spectra even at a ratio of 1:10 (EphA4/Nir2), thus clearly demonstrating that no
direct binding occurred between EphA4 and Nir2 peptide. Strikingly, in the presence of the Nir2 peptide, addition of the unlabeled WT-MSP domain was no longer able to induce shift/disappearance of the EphA4 HSQC peaks even with the ratio increased up to 1:10 (EphA4/MSP). This observation strongly indicates that the binding of the Nir2 peptide to the MSP domain would inhibit its further binding to EphA4, either by triggering the structural change or occupying the EphA4 binding interface on the MSP domain. If considering the fact that the MSP domain show no significant change upon binding to ORP1, a FFAT-containing peptide [12,32], the inhibition of the EphA4-MSP binding by the Nir2 peptide might largely result from the possibility that EphA4 and Nir2 peptide may have overlapped binding interfaces on the MSP domain.

Based on the HSQC titration results, we also constructed the model of the EphA4-MSP complex by HADDOCK and Figure 6a presents the two lowest-energy models. Interestingly, although the overall architecture of the EphA4-MSP complex bears some similarity to the EphA4-ephrinB2 complex [40], some fundamental differences were observed. As previously uncovered, in all Eph-ephrin complexes, the ephrin G-H loop inserts into the hydrophobic ligand-binding channel of Eph receptor constituted by the convex sheet of four β-strands together with the D-E, J-K, and G-H loops (Figure 6b). Previously, by using NMR HSQC titration, we showed that the EphA4 residues on the convex sheets either disappeared or significantly shifted upon binding to ephrinB2 [40]. However, in the EphA4-MSP complex there is no MSP residues inserting into the EphA4 channel. Instead, the MSP E–F loop is found to interact with EphA4 loops including G–H and J–K loops (Figure 6a). This property is strongly supported by our NMR results that no significant perturbation was observed on the residues on the EphA4 convex sheets upon binding to the MSP domain. From this model, binding residues on both MSP and EphA4 are mostly located on loops which are thus highly dynamic. As a consequence, the binding affinity between EphA4 and MSP is expected to be relatively-weak, which is consistent with ITC and NMR results.

Also in the EphA4-MSP model, Thr46 sits in the central part of the EphA4-MSP binding interface (Figure 6a), which rationalizes the experimental observation that the mutation of Thr46 to Ile dramatically abolishes its binding ability to EphA4. On the other hand, in this model EphA4 and FFAT-containing peptide indeed have overlapped binding interfaces on the MSP domain (Figure 6c), thus nicely explaining another experimental observation that the binding of the Nir2 peptide to the MSP domain will inhibit its further interaction with EphA4.

Molecular dynamics (MD) simulations of the WT-/T46I-MSP domains

Our results reveal that the T46I mutation causes no significant disruption of the native MSP structure, but it does lead to ALS. This implies that the protein dynamics may play a key role beyond the static structure, as we recently demonstrated on the SARS 3C-like protease [36]. As such here we utilized the molecular dynamics (MD) simulation to explore the dynamical behavior of the MSP domain as well as the consequence of the T46I mutation.

Figures 7a and 7b present the root-mean-square deviations (RMSD) of backbone atoms for two parallel simulations for both WT- and T46I-MSP domains. It appears that for all simulations, the RMS deviation values increased very rapidly during the first 0.1 ns. This is mostly due to the relaxations of the crystal structures.
upon being solvated in solution. Surprisingly, the WT- and T46I-MSP domains display no significant difference for overall dynamical behaviors, as judged from their similar trajectories and average RMSD values.

Snapshots of two independent simulations are presented in Figures 8a and 8b respectively for the WT- and T46I-MSP domains. As shown in Figures 7c and 7d which present the root-mean-square fluctuation (RMSF) values versus the sequences, although the global patterns of two independent simulations for either WT or T46I are similar, there do exist some significant differences over some local regions. This is due to the fact that the systems behave non-ergodic in 15-ns simulations and as a consequence the results would be influenced by the initial conditions such as velocities. Interestingly, as seen in Figures 7c and 7f, the WT-MSP residues with the RMSF value $>\text{the average value}$ include N-terminal Met1-Val7, Pro21 and Thr23 on A-B loop, Arg50 on C-D loop, Phe76-Ly85 on E-F loop, Pro96-Leu114 containing the unique helical fragment, and C-terminal Phe123-Leu125 (Figure 8c). These residues were also found to be highly dynamic on the min-hr time scale as captured by the H/D exchange experiments.

Overall, the T46I-MSP domain has fluctuation patterns similar to those of the WT-MSP domain (Figures 7c and 7d). Nevertheless, increases of local fluctuations do occur for the T46I-MSP domain. For example, in both simulations (Figures 7c and 7d), several T46I regions show increased dynamics, which include Glu13-Glu15 on the first proline-constrained S-shape loop 
[32], Val44-Arg50 on C-strand and C-D loop covering the mutation site Thr46; Pro80-Val90 on E-F loop and F-strand; Glu103-Val105 on the helical fragment, and Met 115-Lys118 on the G-strand (Figure 8d). On the other hand, we also calculated the hydrogen bond occupancy for the WT and T46I simulations and surprisingly only a small number of hydrogen bonds have the occupancy difference larger than 10% between the WT- and T46I-domains (Table 1). Nevertheless, residues with higher fluctuations (Figure 8d) and significantly-reduced hydrogen bond occupancy in T46I (Figure 8e) also overlap with those experimentally mapped to be critical for binding to EphA4 and Nir2 peptide (Figures 4 and 5). As such, the simulation results suggest that the dynamical changes triggered by the T46I mutation may at least partly account for the loss of the binding affinity to EphA4 and Nir2 peptide.

**Figure 4. Interaction between the WT-/T46I-MSP domains and EphA4.** (a). The ITC titration profile of the binding reaction of the WT-MSP domain to the ligand-binding domain of EphA4 (upper panel); and integrated values for reaction heats with subtraction of the corresponding blank results normalized by the amount of ligand injected versus molar ratio of MSP/EphA4 (lower panel). Superimposition of the two dimensional $^1H$-$^15N$ NMR HSQC spectra of the WT- (b) and T46I- (d) MSP domains in the absence (blue) and presence of the EphA4 ligand binding domain at molar ratios 1:2 (green) and 1:8 (red) (MSP/EphA4). Red letters are used to label residues with disappeared HSQC peaks while blue for residues with shifted HSQC peaks. The MSP structure with the perturbed residues mapped back for the interactions between the WT-MSP and EphA4 (c), and the T46I-MSP and EphA4 (e). Blue is to indicate residues with unperturbed HSQC peaks, while green and red for residues with shifted and disappeared HSQC peaks respectively.
doi:10.1371/journal.pone.0027072.g004
Figure 5. Interaction between EphA4 and WT-/T46I-MSP domain. Superimposition of the two-dimensional $^1$H-$^1$N NMR HSQC spectra of the EphA4 ligand binding domain in the absence (blue) and presence of the WT- (a) and T46I- (c) MSP domains at molar ratios 1:2 (green) and 1:8 (red) (EphA4/MSP). Red letters are used to label residues with disappeared HSQC peaks while blue for residues with shifted peaks. Crystal structure of the EphA4 ligand-binding domain we previously determined (37) with the perturbed residues mapped back for the interaction between EphA4 and WT-MSP (b), and T46I-MSP (d). Blue is to indicate residues with unperturbed HSQC peaks, while green and red for residues with shifted and disappeared peaks respectively.
doi:10.1371/journal.pone.0027072.g005

Figure 6. Docking model for the EphA4-MSP complex. (a). Superimposition of two lowest energy docking model of the EphA4-MSP complex. (b). The crystal structure we previously determined for the EphA4-ephrinB2 complex [40]. (c). The docking model of the EphA4-MSP complex with the FFAT-containing ORP1 peptide displayed according to the VAPA MSP-ORP1 structure [12].
doi:10.1371/journal.pone.0027072.g006
Discussion

Last year, from non-Brazilian kindred the second mutation T46I has been identified on the hVAPB MSP domain which also causes a familial amyotrophic lateral sclerosis [6]. However, so far, it remains completely unknown as how this mutation affects the structure, stability, dynamics and binding function of the MSP domain. In the present study, we aimed to address these issues by utilizing both experimental and computational approaches. Unlike the P56S-MSP domain with the entirely eliminated native structure and binding capacity, the T46I-MSP domain still retains the native secondary and tertiary structures, as evidently shown by extensive CD and NMR characterization. Therefore, totally different from P56S, T46I forms another class of the ALS-causing MSP mutations which are analogous to some SOD1 mutants with the native three-dimensional structure preserved [53,54].

Nevertheless, the T46I mutation does abolish the cooperative urea-unfolding transition and reduce the thermodynamic stability of the MSP domain. This allows the T46I-MSP domain to more easily access the partially- or highly-unfolded intermediates which are prone to aggregation [32–35]. Indeed, if compared to the WT-MSP domain, the T46I-MSP domain is much more prone to aggregation at high protein concentration and temperature. Moreover, as in cells macromolecular solutes are expected to reach concentrations of >300 g/L and occupy >30% of the volume [48,55–58], the tendency of the T46I mutant to aggregate in cells should become more severe. It was once believed that in macromolecular crowded cellular environments, the native state should be stabilized by excluded-volume effects because it occupies less space than the denatured state [48,55]. However, recent studies of protein stability in cells uncover a surprising result; proteins are either unaffected or destabilized in cells [56–58]. Now it is proposed that the destabilization arises from a competition between stabilizing excluded-volume effects and destabilizing nonspecific interactions, in particular electrostatic interactions which become predominant in the crowded cellular environment [56–59]. As such, although the T46I-MSP domain still preserves the native MSP structure in vitro, the T46I-triggered loss of the cooperative unfolding and stability may be sufficient to cause severe aggregation in macromolecular crowded cells, thus rationalizing the previous in vivo observation [6].

Amyotrophic lateral sclerosis (ALS) was described more than 130 years ago, but it still remains a mystery whether any signaling pathway is involved in ALS development. In this regard,
characterization of ALS-causitive mutations on the VAPB MSP domain offers an unprecedented opportunity because two signaling networks have been identified to be associated with the VAPB MSP domain; one linked to lipid trafficking/metabolism via binding to the FFAT-containing proteins; and another connected to Eph-ephrin signaling, by acting as a novel ligand.

![Figure 8. Dynamical behaviors.](image)

(a–b). Structure snapshots (one structure for 1-ns interval) for two independent MD simulations for the WT- (blue) and T46I- (red) MSP domains. (c). The MSP structure in which cyan is utilized to indicate the WT-MSP residues with RMSF values larger than the average. (d). The MSP structure in which red is used to indicate T46I residues whose RMSF values are larger than those of the WT-MSP domain. The two mutation residues causing ALS, P56S and T46I, were displayed as spheres. (e). The MSP structure in which green is used to indicate residues whose hydrogen bonds occupancy difference is larger than 10% between WT and T46I while red is for residues whose hydrogen bonds occupancy difference is larger than 10% between T46I and WT.

doi:10.1371/journal.pone.0027072.g008

### Table 1. Hydrogen Bond Occupancy in MD simulations for the WT- and T46I-MSP Domains.

| Residue | Residue Type | Atom Type | Residue | Residue Type | Atom Type | Average$^a$ [WT] | Average$^a$ [T46I] | Difference$^b$ |
|---------|--------------|-----------|---------|--------------|-----------|-----------------|-----------------|--------------|
| 19      | ARG          | NE        | 124     | GLU          | OE2       | 19.98           | 6.32            | 13.66        |
| 46      | THR          | OG1       | 52      | TYR          | O         | 27.84           | 0.00            | 27.84        |
| 46      | THR          | OG1       | 87      | LYS          | O         | 34.01           | 0.00            | 34.01        |
| 47      | THR          | N         | 87      | LYS          | O         | 86.24           | 64.35           | 21.89        |
| 51      | ARG          | NH1       | 82      | GLU          | OE1       | 14.91           | 3.26            | 11.65        |
| 51      | ARG          | NH1       | 82      | GLU          | OE2       | 17.28           | 1.76            | 15.52        |
| 51      | ARG          | NH1       | 86      | HIS          | NE2       | 55.69           | 13.35           | 42.34        |
| 76      | PHE          | N         | 22      | PHE          | O         | 29.82           | 49.10           | -19.27       |
| 84      | SER          | OG        | 121     | CYS          | O         | 3.90            | 24.24           | -20.34       |

$^a$ The displayed values of the hydrogen bond occupancy are averaged over two independent simulations with 15 ns for WT- [wild-type] and T46I-MSP domains respectively.

$^b$ Only hydrogen bonds with the occupancy difference between WT and T46I >10% are displayed in this table.

doi:10.1371/journal.pone.0027072.t001
for Eph receptors. Here we show that the T46I mutation results in only a 3-fold binding affinity reduction to the N1r2 peptide but dramatically disruption of the binding capability to EphA4. In particular, we reveal that the N1r2 peptide and EphA4 are most likely to have overlapped binding interfaces on the MSP domain and consequently that the binding of the N1r2 peptide prevents the MSP domain from further interacting with EphA4. This thus raises an interesting possibility that the two signaling networks may interplay in vivo. As a consequence, future studies on how they interplay in vivo under physiological and ALS pathological conditions may shed critical light on ALS pathogenesis.

With significant advances in experimental and computational methodologies including NMR spectroscopy and MD simulations, protein dynamics have been recently demonstrated to play a key role in functions [36,60,61]. Here we also experimentally and computationally explored the dynamical behaviors of both WT- and T46I-MSP domains. Our H/D exchange results indicate that even the WT-MSP domain is very dynamic on the min-hr time scale, with fast-exchange rate residues located not only on most loop regions, but also extensively over the helix and β-strands. Furthermore, MD simulations unravel that although the T46I mutation leads to no significant alteration of the overall dynamics, it does trigger increases of fluctuations over several local regions. Most amazingly, the residues with enhanced dynamics appear to be involved in binding to both N1r2 peptide and EphA4. As such, the T46I-triggered enhancement of local dynamics may also contribute to the observed disruption of the binding capability of the MSP domain.

In conclusion, here we reveal that unlike the P56S mutation which completely eliminates the native MSP structure, the T46I mutation results in no dramatic structural disruption and alteration of overall dynamics. Nevertheless, the T46I mutation does lead to the loss of the cooperative unfolding transition and reduction of thermodynamic stability, which consequently renders the T46I-MSP domain to be prone to aggregation at high protein concentrations and temperatures. Furthermore, the T46I mutation leads to only a 3-fold affinity reduction to the N1r2 peptide but remarkable loss in binding to EphA4. In particular, the overlapped interfaces on the MSP domain for binding to EphA4 and N1r2 peptide strongly implies that two signaling networks may functionally interplay in vivo. Future understanding how the interplay alters under ALS pathological conditions may decipher the mystery of ALS pathogenesis.

Acknowledgments

We thank Ms Huiqi Ng for assistance of preparing some protein samples.

Author Contributions

Conceived and designed the experiments: JS. Performed the experiments: SL, HQ LL, JHS JS. Analyzed the data: SL, HQ LL, JS GG. Wrote the paper: JS.

References

1. Brojoi LJ, Miller TM, Cleveland DW (2008) Unravelling the mechanisms involved in motor neuron degeneration in ALS. Annu Rev Neurosci 27: 72-84.
2. Pasinelli P, Brown RH (2006) Molecular biology of amyotrophic lateral sclerosis: insights from genetics. Nat Rev Neurosci 7: 710-723.
3. Nishimura AL, Minne-Neto M, Silva HC, Richter-Costa A, Middleton S, et al. (2004) A mutation in the vesicle-trafficking protein VAPB causes late onset spinal muscular atrophy and amyotrophic lateral sclerosis. Am J Hum Genet 75: 822-31.
4. Nishimura AL, Al-Chalabi A, Zatz M (2005) A common founder for amyotrophic lateral sclerosis type 8 [ALS8] in the Brazilian population. Hum Genet 118: 499-500.
5. Hirano M (2008) VAPB: new genetic clues to the pathogenesis of ALS. Neurology 70: 1161-2.
6. Chen HJ, Hagstrom G, Chai A, Withers J, Morris A, et al. (2010) Characterization of the properties of a novel mutation in VAPB in familial amyotrophic lateral sclerosis. J Biol Chem 285: 40266-81.
7. Skelhel PA, Martin KC, Kandel ER, Bartch D (1995) A VAMP-binding protein from Aplysia required for neurotransmitter release. Science 269: 1580-1583.
8. Nishimura Y, Narayashi M, Inada H, Tanaka T (1996) Molecular cloning and characterization of mammalian homologues of vesicle-associated membrane protein-associated [VAMP-associated] proteins. Biochem Biophys Res Commun 225: 21-26.
9. Skelhel PA, Fabio Fine R, Kandel ER (2000) Mouse VAP33 is associated with the endoplasmic reticulum and microtubules. Proc Natl Acad Sci USA 97: 1101-1106.
10. Sousan L, Burakov D, Daniels MP, Toister-Achituv M, Porta A, et al. (1999) ERG30, a VAP-33-related protein, functions in protein transport mediated by COPI vesicles. J Cell Biol 146: 301-311.
11. Amari R, Ramachandran S, Sahana H, Lev S (2003) Differential regulation of endoplasmic reticulum structure through VAP-Nir protein interaction. J Biol Chem 278: 5934-5944.
12. Kaiser SE, Brückner JH, Relein AR, Fenn TD, Walter P, et al. (2005) Structural basis of FFAT motif-mediated ER targeting. Structure 13: 1035-1045.
13. Loewen CJ, Levine TP (2005) A highly conserved binding site in vesicle-associated membrane protein-associated protein (VAP) for the FFAT motif of lipid-binding proteins. J Biol Chem 280: 14097-14104.
14. Ohkounen VM (2004) Oyster binding protein and its homologs: new regulatory factors involved in lipid metabolism. Curr Opin Lipidol 15: 321-327.
15. Holbien JC, Levine TP (2005) Lipid traffic: floppy drives and a superhighway. Nat Rev Mol Cell Biol 6: 209-220.
16. Levine T, Loewen C (2006) Inter-organellar membrane contact sites: through a glass, darkly. Curr Opin Cell Biol 18: 371-379.
17. Kawanou M, Kumagai K, Nishijima M, Hanada K (2006) Efficient trafficking of ceramide from the endoplasmic reticulum to the Golgi apparatus requires a VASP-associated protein-interacting FFAT motif of CERT. J Biol Chem 281: 30279-30289.
18. Perry RJ, Ridgway ND (2006) Oyster-binding protein and vesicle-associated membrane protein-associated protein are required for sterleodependent activation of the ceramide transport protein. Mol Biol Cell 17: 2604-2616.
19. Wyles JP, McMaster CR, Ridgway DN (2002) Vesicle-associated membrane protein-associated protein-A (VAP-A) interacts with the oyster-binding protein to modify export from the endoplasmic reticulum. J Biol Chem 277: 29908-29918.
20. Weir ML, Xie H, Klip A, Trimble SW (2001) VAP-A binds promiscuously to both v- and tSNAREs. Biochem Biophys Res Commun 286: 616-621.
21. Minne-Neto M, Ramos CR, Pimenta DC, Luz JS, Nishimura AL, et al. (2007) A mutation in human VAP-B--MSP domain, present in ALS patients, affects the interaction with other cellular proteins. Protein Expr Purif 53: 139-46.
22. Teuling E, Ahmed S, Haasdijk E, Demmers J, Steinmetz MO, et al. (2007) Motor neuron disease-associated mutant vesicle-associated membrane protein-associated protein (VAP, B recruits wild-type VAP into endoplasmic reticulum-derived tubular aggregates. J Neurosci 27: 9801-15.
23. Ratnaparkhi A, Lawless GM, Schweizer FE, Gohilani P, Jackson GR (2006) A Drosophila model of ALS: human ALS-associated mutation in VAP33A suggests a dominant negative mechanism. PLoS One 1:e2354.
24. Prosser DC, Tran D, Gougeon PY, Verly C, Ngue JK (2008) FFAT rescues VAPA-mediated inhibition of ER-to-Golgi transport and VAPB-mediated ER aggregation. J Cell Sci 121 (Pt 16): 3052-61.
25. Kanekura K, Nishimoto I, Aso S, Matsusaka M (2006) Characterization of amyotrophic lateral sclerosis-linked P56S mutation of vesicle-associated membrane protein-associated protein B (VAPB/ALS8). J Biol Chem 291: 36025-33.
26. Goktas G, Middleton S, Kremer AM, Wardrop C, Hannah M, et al. (2006) VAPB interacts with and modulates the activity of AIF6. Hum Mol Genet 15: 1517-26.
27. Kanekura K, Suzuki H, Aso S, Matsusaka MER (2009) Stress and Unfolded Protein Response in Amyotrophic Lateral Sclerosis. Mol Neurobiol 39: 81-9.
28. Suzuki K, Kanekura K, Levine TP, Kohno K, Ohkounen VM, et al. (2009) ALS-linked P56S-VAPB, an aggregated loss-of-function mutant of VAPB, predisposes motor neurons to ER stress-related death by inducing aggregation of co-expressed wild-type VAPB. J Neurochem 108: 973-985.
29. Tsuda H, Han SM, Yang Y, Tong C, Lin YQ, et al. (2008) The amyotrophic lateral sclerosis β protein VAPB is cleaved, secreted, and acts as a ligand for Eph receptors. Cell 133: 963-77.
30. Ackerman SL, Cox GA (2008) From ER to Eph receptors: new roles for VAP proteins. Cell 133: 949-51.
31. Pasquale, B E (2008) Eph-ephrin bidirectional signaling in physiology and disease. Cell 133: 38-52.
32. Shi J, Lua S, Tong JS, Song J (2010) Elimination of the native structure and solubility of the VAPB MSP domain by the Pro56Ser mutation that causes amyotrophic lateral sclerosis. Biochemistry 49: 3807-97.
33. Song J (2009) Insight into "Insoluble Proteins" with Pure Water. FEBS Lett 583: 953–959.
34. Li M, Liu J, Ran X, Fang M, Shi J, et al. (2006) Resurrecting Abandoned Proteins with the Pure Water: CD and NMR studies of protein fragments solubilized in salt-free water. Biophys J 91: 4201–4209.
35. Liu J, Song J (2009) Insights into Protein Aggregation by NMR Characterization of Insoluble SH3 Mutants Solubilized in Salt-Free Water. PLoS ONE 4: e7601.
36. Shi J, Han N, Lim L, Lue S, Sivaraman J, et al. (2011) Dynamically-driven inactivation of the catalytic machinery of the SARS 3C-like protease by the N214A mutation on the extra domain. PLoS Comput Biol 7: e1001014.
37. Qin H, Shi J, Noberini R, Pasquale EB, Song J (2008) Crystal structure and NMR binding reveal that two small molecule antagonists target the high affinity ephrin-binding channel of the EphA4 receptor. J Biol Chem 283: 29473–29484.
38. Pace CN, Vajdos F, Fee L, Grimsley G, Gray T (1995) How to measure and predict the molar absorption coefficient of a protein. Protein Sci 4: 2411–2423.
39. Vranken WF, Boucher W, Stevens TJ, Fogh RH, Pajon A, et al. (2005) The CCPN data model for NMR spectroscopy: development of a software pipeline. Proteins 59: 687–96.
40. Qin H, Noberini R, Huan X, Shi J, Pasquale EB, et al. (2010) Structural characterization of the EphA4-Ephrin-B2 complex reveals new features enabling Eph-ephrin binding promiscuity. J Biol Chem 285: 644–54.
41. Qin H, Pu HX, Li M, Ahmed S, Song J (1998) Identification and structural mechanism for a novel interaction between a ubiquitin ligase WWP1 and Nogo-A, a key inhibitor for central nervous system regeneration. Biochemistry 47: 13647–58.
42. de Vries SJ, van Dijk ADJ, Krzeminski MI, van Dijk M, Thureau A, et al. (2007) HADDOCK versus HADDOCK: New features and performance of HADDOCK2.0 on the CAPRI targets. Proteins 69: 726–733.
43. Brunger AT, Adams PD, Clore GM, DeLano WL, Gros P, et al. (1998) Crystallography & NMR System: A New Software Suite for Macromolecular Structure Determination. Acta Crystallographica Section D 54: 905–921.
44. Hess B, Kutzner C, van der Spoel D, Lindahl E (2008) GROMACS 4: Algorithms for Highly Efficient, Load-Balanced, and Scalable Molecular Simulation. J Chem Theory Comput 4: 433–447.
45. Lindorff-Larsen K, Piana S, Palmo K, Maragakis P, Klepeis JL, et al. (2010) Improved side-chain torsion potentials for the Amber ff99SB protein force field. Protein 78: 1950–8.
46. Schlick T (2002) Molecular Modeling and Simulation: An Interdisciplinary Guide. New York: Springer-Verlag.
47. Hess B, Bekker H, Berendsen HJC, Fraaije GEM (1997) LINCS: A linear constraint solver for molecular simulations. J Comput Chem 18: 1463–1472.
48. Ellis RJ (2001) Macromolecular crowding: obvious but underappreciated. Trends Biochem Sci 26: 597–604.
49. Song J, Jamin N, Gilquin B, Vita C, Menez A (1999) A gradual disruption of tight side-chain packing: 2D 1H-NMR characterization of acid-induced unfolding of CHABII. Nature Struct Biol 6: 129–34.
50. Wei Z, Song J (2005) Molecular mechanism underlying the thermal stability and pH-Induced unfolding of CHABII. J Mol Biol 349: 205–218.
51. Krishna MM, Hoang L, Lin Y, Englander SW (2004) Hydrogen exchange methods to study protein folding. Methods 34: 51–64.
52. Ran X, Qin H, Liu J, Fan JS, Shi J, et al. (2008) NMR structure and dynamics of human ephrin-B2 ectodomain: The functionally critical C-D and G-H loops are highly dynamic in solution. Proteins 72: 1019–1029.
53. Banfi L, Bertini I, Boca M, Calderone V, Cantini F, et al. (2009) Structural and dynamic aspects related to oligomerization of apo SOD1 and its mutants. Proc Natl Acad Sci U S A 106: 9680–5.
54. Nordlund A, Leinartaitie L, Sarabojo K, Aisenbrey C, Grobner G, et al. (2009) Functional features cause misfolding of the ALS-provoking enzyme SOD1. Proc Natl Acad Sci U S A 106: 9667–72.
55. Minton, P A (1981) Excluded volume as a determinant of macromolecular structure and reactivity. Biopolymers 20: 2093–2120.
56. Inomata K, Ohno A, Tochio H, Isogai S, Tenno T, et al. (2009) High-resolution multi-dimensional NMR spectroscopy of proteins in human cells. Nature 458: 106–9.
57. Miklos AC, Sarkar M, Wang Y, Pelak GJ (2011) Protein crowding tunes protein stability. J Am Chem Soc 133: 7116–20.
58. Schlesinger AP, Wang Y, Tadeo X, Millet O, Pelak GJ (2011) Macromolecular crowding fails to fold a globular protein in cells. J Am Chem Soc 133: 8092–5.
59. Lase T, Dzemler B (2011) A postreductionist framework for protein biochemistry. Nat Chem Biol 7: 331–4.
60. Karsplus M, Kuriyan J (2005) Molecular dynamics and protein function. Proc Natl Acad Sci U S A 102: 6679–6685.
61. Smock RG, Gierasch ML (2009) Sending Signals Dynamically. Science 324: 190–203.